Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;9(21):7914-7924.
doi: 10.1002/cam4.3393. Epub 2020 Sep 25.

Particle beam radiation therapy for sinonasal malignancies: Single institutional experience at the Shanghai Proton and Heavy Ion Center

Weixu Hu  1   2 , Jiyi Hu  1   2 , Qingting Huang  1   2 , Jing Gao  1   2 , Jing Yang  1   2 , Xianxin Qiu  1   2 , Lin Kong  2   3 , Jiade J Lu  1   2
Affiliations

Particle beam radiation therapy for sinonasal malignancies: Single institutional experience at the Shanghai Proton and Heavy Ion Center

Weixu Hu et al. Cancer Med. 2020 Nov.

Abstract

Background: Sinonasal malignancies (SNM) include malignant neoplasms of various histologies that originate from the paranasal sinuses or nasal cavity. This study reported the safety and efficacy of particle-beam radiation therapy (PBRT) for the treatment of sinonasal malignancies.

Methods and materials: One-hundred-and-eleven patients with nonmetastatic sinonasal malignancies received definitive (82.9%) or salvage (31.5%) PBRT. The majority (85.6%) of patients presented with T3/4 disease, and only 19 (17.1%) had R0 or R1 resection. Seventy (63.1%) patients received carbon-ion radiotherapy (CIRT), 37 received proton radiotherapy (PRT) followed by CIRT boost, and 4 received PRT alone. Prognostic factors were analyzed using Cox regression for univariate and multiple regression. Toxicities were reported using the Common Terminology Criteria for Adverse Events (version 4.03).

Results: The median follow-up was 20.2 months for the entire cohort. The 2-year local progression-free survival (LPFS), regional progression-free survival (RPFS), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS) rates were 83%, 97.2%, 85.9%, 66%, and 82%, respectively. Re-irradiation and large GTV were the significant factors for OS. Melanoma and sarcoma patients had significantly higher distant metastatic rate, and poorer OS and PFS. Late toxicity occurred in 22 (19.8%) patients, but only 4 (3.6%) patients experienced grades 3-4 late toxicity.

Conclusions: Particle-beam radiation therapy results in excellent local-regional control with extremely low serve toxicities for patients with SNM. Sarcoma and melanoma were featured with a greater risk of death from distant dissemination. Patients who underwent re-irradiation had significantly worse OS. PBRT is feasible and safe in the management of SNM.

Keywords: carbon-ion radiotherapy; nasal and paranasal sinus malignancies; particle-beam radiation therapy; proton radiotherapy; sinonasal malignancies.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

FIGURE 1
FIGURE 1
Two‐year survival rates for entire cohorts: overall survival (A), progression‐free survival (B), local progression‐free survival (C), regional progression‐free survival (D), and distant metastasis‐free survival (E)
FIGURE 2
FIGURE 2
Overall survival (A), progression‐free survival (B), and distant metastasis‐free survival (C) with sarcoma vs melanoma vs other histologies
FIGURE 3
FIGURE 3
Overall survival with radiation therapy (RT)‐naive vs re‐irradiation
See this image and copyright information in PMC

References

    1. Dulguerov P, Jacobsen MS, Allal AS, Lehmann W, Calcaterra T. Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer. 2001;92:3012‐3029. - PubMed
    1. Cantù G, Bimbi G, Miceli R, et al. Lymph node metastases in malignant tumors of the paranasal sinuses: prognostic value and treatment. Arch Otolaryngol Head Neck Surg. 2008;134:170‐177. - PubMed
    1. Myers LL, Nussenbaum B, Bradford CR, Teknos TN, Esclamado RM, Wolf GT. Paranasal sinus malignancies: an 18‐year single institution experience. Laryngoscope. 2002;112:1964‐1969. - PubMed
    1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Head and Neck Cancers, Version 1. 2020 ‐ February 12.2020.
    1. Daly ME, Chen AM, Bucci MK, et al. Intensity‐modulated radiation therapy for malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys. 2007;67:151‐157. - PubMed

Publication types

MeSH terms